BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21792626)

  • 1. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
    Massarweh S; Tham YL; Huang J; Sexton K; Weiss H; Tsimelzon A; Beyer A; Rimawi M; Cai WY; Hilsenbeck S; Fuqua S; Elledge R
    Breast Cancer Res Treat; 2011 Oct; 129(3):819-27. PubMed ID: 21792626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
    Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
    Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
    Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
    Smith IE; Walsh G; Skene A; Llombart A; Mayordomo JI; Detre S; Salter J; Clark E; Magill P; Dowsett M
    J Clin Oncol; 2007 Sep; 25(25):3816-22. PubMed ID: 17679728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
    Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
    JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
    Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; Peston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC
    Lancet Oncol; 2005 Jun; 6(6):383-91. PubMed ID: 15925816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
    Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
    Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
    Robertson JF; Dixon JM; Sibbering DM; Jahan A; Ellis IO; Channon E; Hyman-Taylor P; Nicholson RI; Gee JM
    Breast Cancer Res; 2013 Mar; 15(2):R18. PubMed ID: 23497452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
    Bergh J; Jönsson PE; Lidbrink EK; Trudeau M; Eiermann W; Brattström D; Lindemann JP; Wiklund F; Henriksson R
    J Clin Oncol; 2012 Jun; 30(16):1919-25. PubMed ID: 22370325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
    Robertson JF; Lindemann JP; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Emerson L; Dean A; Ellis MJ
    Breast Cancer Res Treat; 2012 Nov; 136(2):503-11. PubMed ID: 23065000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).
    Tryfonidis K; Basaran G; Bogaerts J; Debled M; Dirix L; Thery JC; Tjan-Heijnen VC; Van den Weyngaert D; Cufer T; Piccart M; Cameron D;
    Eur J Cancer; 2016 Jan; 53():144-54. PubMed ID: 26724641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
    Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
    Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
    Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
    Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
    Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.